Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
2.185
+0.025 (1.16%)
Nov 21, 2024, 10:42 AM EST - Market open
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Akoya Biosciences stock have an average target of 4.40, with a low estimate of 3.00 and a high estimate of 7.50. The average target predicts an increase of 101.37% from the current stock price of 2.19.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AKYA stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 4 | 4 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 4 | 4 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +37.30% | Nov 19, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades $7 → $5 | Strong Buy → Hold | Downgrades | $7 → $5 | +128.83% | Nov 15, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $3.5 | Strong Buy | Maintains | $6 → $3.5 | +60.18% | Nov 15, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +83.07% | Aug 13, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $4 → $3 | Buy → Hold | Downgrades | $4 → $3 | +37.30% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
100.17M
from 96.63M
Increased by 3.66%
Revenue Next Year
118.38M
from 100.17M
Increased by 18.18%
EPS This Year
-1.04
from -1.43
EPS Next Year
-0.56
from -1.04
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 106.2M | 127.6M | 162.4M | ||
| Avg | 100.2M | 118.4M | 138.1M | ||
| Low | 93.5M | 106.8M | 113.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9.9% | 27.4% | 37.2% | ||
| Avg | 3.7% | 18.2% | 16.7% | ||
| Low | -3.3% | 6.6% | -3.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.90 | -0.40 | -0.04 | ||
| Avg | -1.04 | -0.56 | -0.34 | ||
| Low | -1.16 | -0.77 | -0.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.